Major Topic. Malignant Melanoma Plastic and Reconstructive Surgery R3 陸尊惠 /VS 吳瑞星

Similar documents
Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Melanoma: The Basics. What is a melanocyte?

Clinical Pathological Conference. Malignant Melanoma of the Vulva

World Articles of Ear, Nose and Throat Page 1

WHAT DOES THE PATHOLOGY REPORT MEAN?

Mechanical versus bioprosthetic valve. Intern: Supervisor: VS

Clinical characteristics

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

Melanoma Case Scenario 1

Malignant Melanoma Early Stage. A guide for patients

Melanoma Case Scenario 1

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

Corporate Medical Policy

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center

Technicians & Nurses Program

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

Melanoma. Lynn Schuchter, M.D. Associate Professor of Medicine Abramson Cancer Center of the University of Pennsylvania

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018

Melanoma Quality Reporting

Merkel Cell Carcinoma Case # 2

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

Radiology Pathology Conference

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Clinical indications for positron emission tomography

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone

Kentaro Tanaka, 1 Hiroki Mori, 1 Mutsumi Okazaki, 1 Aya Nishizawa, 2 and Hiroo Yokozeki Introduction. 2. Case Presentation

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012

Patient Information. Age: 8 y/o Sex: Female. Date of Admission: Date of Discharge:

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR

BACK TO TABLE OF CONTENTS FOCUS ON MELANOMA Oncology Annual Report BAPTIST HEALTH LEXINGTON ONCOLOGY ANNUAL REPORT

Subject ID: I N D # # U A * Consent Date: Day Month Year

Management of Neck Metastasis from Unknown Primary

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Case Presentation and Discussion on GI Bleeding Nolan Ortega Aludino, M.D.

Chief complaint. A mass at right chest

MELANOMA. Some people are more likely to get a m Melanoma than others:

Update on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD

Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035

North of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma

Integumentary System

PET in Rectal Carcinoma

Da Costa was the first to coin the term. Marjolin s Ulcer: A Case Report and Literature Review. Case Report. Introduction

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

Case conference. Welcome Dr. Lawrence Tierney

General information about skin cancer

Surgical Issues in Melanoma

MELANOMA. 4 Fitzroy Square, London W1T 5HQ Tel: Fax: Registered Charity No.

Imaging in gastric cancer

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine

STAGING, BIOPSY AND NATURAL HISTORY OF TUMORS SCOTT D WEINER MD

Case Scenario 1. Discharge Summary

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

NAACCR Webinar Series 1

Current Therapy of Cutaneous Melanoma

Clinical Radiological Pathological Conference

Skin Cancer - Non-Melanoma

Dr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland

Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG

Esophageal Cancer Initially Thought to be Accompanied by a Solitary Metastasis to an Intrathoracic Paraaortic Lymph Node

Guideline for the Management of Vulval Cancer

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC

11/21/13 CEA: 1.7 WNL

Subject Index. Dry desquamation, see Skin reactions, radiotherapy

Rebecca Vogel, PGY-4 March 5, 2012

Directly Coded Summary Stage Melanoma

Oral and Maxillofacial Surgery Department

Dermoscopy: Recognizing Top Five Common In- Office Diagnoses

Protocol applies to melanoma of cutaneous surfaces only.

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

MELANOMA: HANDS-ON OR HANDS-OFF?

PET/CT Frequently Asked Questions

Periocular Malignancies

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

Krunal Amin 7/17/2010 Josh Cannon Topics in Biology

ORAL MELANOMA Definition Epidemiology Clinical Presentation

Melanoma. Exceptional healthcare, personally delivered

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

RECTAL CANCER CLINICAL CASE PRESENTATION

Printed by Martina Huckova on 10/3/2011 3:04:54 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive

CANCER. Mrs. Davis Health Education

Epidemiology. Objectives 8/28/2017

Carcinoma of Unknown Primary site (CUP) in HEAD & NECK SURGERY

MOHS MICROGRAPHIC SURGERY: AN OVERVIEW

Quiz. b. 4 High grade c. 9 Unknown

SAMPLING OF POST NEPHRECTOMY CANCER CARE (5)

Transcription:

Major Topic Malignant Melanoma Plastic and Reconstructive Surgery R3 陸尊惠 /VS 吳瑞星

Patient Data Name: OOO Age: 70 Gender: Male Date of admission: Day 1

Chief Complaint Black skin tumor at the back of the knee, noted for two months

Present Illness Dark brown, blackish patch at the back of the right knee noted for 2 months No itching or bleeding, asymptomatic Visited our dermatology department Biopsy: Melanoma Proliferation of hyperchromatic atypical epithelioid neoplastic cells growing in nests in the epidermis and dermis Immunostain: positive for HMB-45 and MITF Tumor invades and expands the papillary dermis (Clark level III) and measures less than 1mm in thickness Ulceration, vascular space permeation and perineural invasion are not found

Past History Cardiac dysrhythmia, with regular OPD follow-up and medical control (Warfarin 4mg/day) No operation history Non-smoker, occasional social drinking No food or drug allergies

Physical Examination Conscious clear E4M6V5 Body height: 177cm, weight: 70kg Vital signs: BP 128/70, HR 64, RR 20, BT 36 HEENT: grossly normal, conjunctiva pink, sclera anicteric, pupils isocoric, neck supple, no LAP Chest: symmetric expansion, clear breathing,sound, regular heart beat, no murmur Abdomen: flat, soft, no tenderness, bowel sound normoactive, no flank knocking pain Extremities: freely movable, sutures at right popliteal region, wound clear, no palpable lymph nodes at inguinal region

Laboratory Data WBC: 5140/mm3, Seg 49.7%, Lym 38.3% Hb: 14.3 g/dl PLT: 145000/mm3 GOT/GPT: 19/18 IU/L BUN/Cr: 15/1.1 mg/dl Na/K: 139/3.6 mmol/l PT: 14.9/11.9 sec aptt: 35.7/31.0 sec INR: 1.51

Positron Emission Tomography Scan Regionally increased radiotracer uptake in nasal cavity, oropharynx, colon, rectum and testes. The regional radiotracer uptake persisted in the delayed images acquired about 3 hours postinjection. The focal glucose hypermetabolism cannot be ascertained solely by FDG PET result. It may be due to normal physiological glucose metabolism and without clinical significance Otherwise, no other obvious abnormally increased radiotracer uptake is identified elsewhere in the body

Op Wide excision + elective lymph node dissection + split thickness skin graft 2.5cm surgical margin Intraoperative frozen section: Circumferential and basal margins free of malignancy

Pathology Skin, posterior knee, popliteal fossa, right, status post biopsy, wide excision for frozen section --- residual melanoma, Clark level III, 1mm in thickness, without ulceration Surgical margin, basal and circumferential --- free of malignancy Lymph node, inguinal area, right --- free of metastasis (0/11)

Discussion Malignant Melanoma

Introduction Malignant transformation of melanocyte Can occur anywhere melanocytes are present Most common tissue in which melanomas arise is the skin Incidence: varies widely, reflective of variation in genetic, phenotypic, and ultraviolet exposure risk factors US: 15 per 100,000 Australia: 45 per 100,000 China: <1 per 100,000

Risk Factors Exposure to UV radiation Intermittent, damaging exposure History of severe sunburn (blistering or pain for more than 2 days) confers a twofold increase in risk Chronic and occupational exposure confers less of a risk for melanoma, more of a risk for basal or squamous cell cancers Genetic predisposition Fair skin, blue eyes, red hair, easy freckling

Diagnosis Biopsy of a clinically suspicious lesion High-risk lesion (ABCDE Criteria) Asymmetry Border irregularity Color variegation Diameter >6mm Evolution 5% of melanomas are nonpigmented In earliest stages of development, most melanomas are <6mm in diameter Recent change or bleeding or itching: high risk

Workup Chest radiograph, serum lactic dehydrogenase (LDH) Head and neck primary lesion: head and neck CT or PET scan Clinically positive nodes in head or neck or groin: CT Distant metastasis: complete blood count, alkaline phosphatase, LDH, creatinine, CT of chest, abdomen, pelvis; MRI of brain; bone scan if symptomatic

Staging Revised American Joint Committee on Cancer (AJCC) staging system published in August 2001 Major changes: T classification breakpoints of whole-integer thichness Tumor ulceration is included as a factor in the T classification and presence of ulceration upstages patients with stages I, II and III disease Clark level is now used only to subclassify T1 (<1mm) tumors Number of metastatic lymph nodes is prognostically significant Site of distant metastasis and presence of elevated LDH are used to subclassify M stage

5-Year Survival Rates Stage I: 92% Stage II: 68% Stage III: 45% Stage IV: 10%

Management Primary treatment for virtually all melanomas is surgical Wide excision of primary tumor Removal of regional lymph nodes that are involved or at high risk for involvement

Wide Local Excision 5-cm standard margin (normal-appearing skin around the lesion, soft tissue down to, and including, muscle fascia) was the standard of care through most of 20 th century Late 1970s: series of retrospective reviews suggested narrower margins do not lead to significantly higher mortality or local recurrence rates

Archives of Surgery 2007 Excision Margins for Primary Cutaneous Melanoma: Updated Pooled Analysis of Randomized Controlled Trials Meta-analysis of 5 published prospective randomized trials evaluating the effect of width of excision margins on survival and recurrence

Results Total 3313 patients 1639 narrow excision 1674 wide excision 2220 had tumors less than 2mm None of the 5 trials demonstrated a survival advantage for wide excision margins Overall mortality was no significantly improved by performing wide excision margins No statistically significant difference in prevalence of locoregional recurrence between the two groups No statistically significant difference in incidence of local recurrence

WHO Melanoma Program Randomized patients with melanomas <2mm thick to receive wide local excision with 1 vs. 3 cm margin 612 patients, mean follow-up of 55 months No significant differences in disease-free survival, overall survival, or subsequent development of metastatic disease 3 patients developed local recurrence, all were in the 1- cm excision group and each had a primary lesion with a thickness > 1mm Authors concluded that for patients with primary lesions <1mm, a 1-cm margin excision is safe and effective

Intergroup Melanoma Trial Randomized patients with melanomas between 1 and 4 mm thick to receive excision with 2 vs. 4-cm margin 486 patients, median follow-up 6 years No significant difference in local recurrence, metastases, or 5-year survival Authors conclude that for 1 to 4mm thick melanoma patients, margin of excision could be safely reduced to 2 cm

British Trial Randomized 900 patients with melanomas >2mm to receive 1 vs. 3 cm margin wide excisions Median follow-up 60 months Significantly higher locoregional recurrence (37% vs. 32%) and disease-specific mortality (28% vs. 23%) in the group with narrower margins Limitations of study: most of the difference results from a higher nodal recurrence rate in the narrow margin group; there was no difference in local recurrence rate Overall survival was unaffected Authors conclude that to optimize disease-specific survival, use of a 1-cm margin should be avoided in patients with melanoma >2mm

There are no randomized trials to guide treatment standards for patients with thick melanomas (>4mm) A wider margin should be used unless it unduly increases morbidity Generally, a margin of 2 to 3cm is recommended for patients with melanomas >4mm in thickness

Current Recommendations

Lymphadenectomy Controversial Disagreement regarding excision of clinically uninvolved nodes Potential benefit of elective lymph node dissection is based on the dogma of sequential spread of metastatic disease to the regional lymph node prior to distant organs

Intergroup Melanoma Surgical Trial 740 patients randomized to receive ELND vs. observation, average follow-up of 7.4 years Patients with melanomas <1mm and >4mm were excluded from study There was no significant difference in survival There was significant survival advantage conferred by ELND in patients younger than 60 and for tumors between 1 and 2mm thick without ulceration Data suggest that there may be survival advantages for ELND in certain subgroups

Thank You